It is estimated the global market for antibody drugs will reach $114.6 billion by 2022, up from $84.5 billion in 2017, with a 6.3% annual growth rate. In comparison, the global market for research antibodies (monoclonal and polyclonal) reached almost $3 billion this year, with a similar annual growth rate.
In 2016, monoclonal antibody drugs had the largest share of the market in autoimmune diseases with about 46.1%. Solid tumors, lymphoma and leukemia, and other diseases had market shared of 24.2%, 13.2% and 16.5%, respectively.
Humanized monoclonal antibodies (mAbs) are the largest segment in terms of revenue, followed by other monoclonal antibody categories such as human, chimeric and murine.
Diagnostic antibodies market is also a fast growing industry, globally exceeding ten billion dollars annually.
(Source of statistics BCC Research)
In 2016, monoclonal antibody drugs had the largest share of the market in autoimmune diseases with about 46.1%. Solid tumors, lymphoma and leukemia, and other diseases had market shared of 24.2%, 13.2% and 16.5%, respectively.
Humanized monoclonal antibodies (mAbs) are the largest segment in terms of revenue, followed by other monoclonal antibody categories such as human, chimeric and murine.
Diagnostic antibodies market is also a fast growing industry, globally exceeding ten billion dollars annually.
(Source of statistics BCC Research)
RSS Feed